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Abstract
Background: Impairment in auditory sensory gating (ASG) has been documented in
alcohol dependence [1]. Likewise, it has been shown that ASG becomes abnormal
during alcohol administration in otherwise healthy individuals [2]. Patterns of gating
abnormality associated with alcohol use are likely associated with an alcohol responsive
neurochemical like glutamate (Glu), particularly since it is well-established that alcohol
affects NMDA receptors and that glutamatergic functioning is abnormal in both
acute alcohol use and in alcohol dependence [3]. Hence, a link between Glu
metabolite levels and ASG was hypothesized. It was first hypothesized that Glu
and ASG abnormality would be found in groups with alcohol dependence. A second
hypothesis was that across groups, greater Glu would predict reduced ASG.
Methods: Groups were comprised of healthy, non-drinking controls (Controls, N = 4),
individuals with current alcohol dependence (AUD-current, N = 6), and with alcohol
dependence in remission for at least 1 year (AUD-remission, N = 6). Participants
underwent a diagnostic assessment for alcohol consumption, MRI, 1H-MRS for in
vivo assessment of Glu and other metabolites, and MEG scanning during a
paired click protocol. ASG was computed as the ratio of the source strength of
the 50 ms component in the event related field (ERF) to the second click in the
pair divided by the source strength of the 50 ms component to the first click in
the pair.
Results: Univariate MANOVAs controlling for age and gender revealed a significant
effect for group on Glu and ASG, such that ASG ratios were significantly elevated,
implying weakened gating. Glu concentration was reduced in AUD-current relative to
the other two groups. Further analysis revealed that when additionally controlling for
the group effect, reduced Glu predicted increasing impairment in ASG.
Conclusions: The overall results were consistent with the hypothesis that differences in
Glu metabolite levels associated with alcohol dependence result in impaired ASG.
Keywords: Magnetoencephalography, MEG, Proton magnetic resonance spectroscopy,
1H-MRS, Auditory sensory gating, Paired click paradigm, Auditory event related
potential
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Background
Auditory sensory gating (ASG) assesses the degree to which redundant auditory informa-
tion is filtered very early in perceptual processing and is often assessed in terms of the 50
millisecond positivity in the auditory event related potential (AERP; [1, 4, 5]). In a paired
click paradigm, pairs of auditory click stimuli are presented with a half-second interstimu-
lus interval. The peak amplitude of the auditory event-related potential (ERP) of the sec-
ond click in the pair (S2) can be divided by the ERP peak amplitude of the first click (S1)
to create a gating ratio—a metric of the extent to which filtering is successful. This model
of auditory sensory gating (ASG) has been extensively investigated as an endophenotype
for schizophrenia, as sensory gating ratios in this population are reliably higher than in
control populations.
Recent research has also indicated that gating abnormalities are associated with alcohol
dependence, but much work remains to determine the extent to which gating may be an
effect of alcohol use, and if so, what the neural mechanisms are by which gating becomes
impaired. Increases in ASG ratios occur with acute alcohol ingestion [2] and the level of
ASG impairment in patients with a history of alcohol dependence has been reported to be
equal to that seen in schizophrenia [1]. Together, these results suggest that chronic alcohol
dependence may result in a lifelong gating impairment. Neurochemical mechanisms
underlying ASG have long been of interest in schizophrenia research and a sequence
of neurochemical events associated with ASG has recently been described in detail
[6]. Excitatory glutamatergic afferents relay auditory sensory information about S1 to
hippocampal pyramidal neurons that modulate the response in auditory cortex (ul-
timately measured as the P50 AERP). A branch of the glutamatergic afferents also ex-
cites inhibitory interneurons that serve to reduce subsequent activation of the
pyramidal cells. Excitatory cholinergic afferents to these interneurons from the fim-
bria fornix serve to maintain the gating mechanism, and “conditioning” of auditory
sensation can last for as long as several seconds [6].
In alcohol use disorders (AUD), glutamate (Glu) concentrations, measured in vivo using
proton magnetic resonance spectroscopy (1H-MRS) in anterior cingulate cortex [3, 7], [8]),
frontal white matter [9], and insula [7] are abnormal. In a cross-sectional study, Mon and
colleagues [10] showed recovery of Glu levels from 1 to 5 weeks of abstinence in an AUD
population. Consistent with Mon et al [10], elapsed time since initiation of successful
remission predicted a return of Glu levels to that of controls [3]. Additionally, Glu may play
a role in AUD relapse, as levels of both craving and Glu are positively correlated in AUD
[11].
Given the clinical importance of understanding alcohol dependence and the associated
sensory and behavioral complications that arise, it is worthwhile investigating a possible link
between impaired ASG and glutamate levels in alcohol dependence. To do so 1H-MRS
neurometabolite concentrations and MEG M50 sensory gating data were collected in
groups of healthy controls (Controls), current alcohol dependent (AUD-current) and fully
remitted alcohol dependent (AUD-remission) individuals. It was hypothesized that Glu
concentration would be abnormal in the AUD groups, and that Glu would account for
independent variance in sensory gating ratios across groups. An anterior cingulate cortex
(ACC) voxel was selected as the site for 1H-MRS measurement due to the high reliability
and validity of neurometabolite measurement in this region [12, 13]. ACC was also selected
because M50 modulation is known to have a strong fronto-temporal component [14] and
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differences in ACC Glu concentration affect fronto-temporal connectivity [15]. Magnetoen-
cephalography (MEG) was used for assessment of gating because MEG temporal resolution
is suitable for measurement of the AERF M50, and assessment of ASG in terms of left- and
right-hemisphere M50 dipole activity permits investigation of subtle hemispheric differences
that may go undetected using other means [5, 16]. In addition, since MEG-assessed signal
strength is sensitive to Glu concentration in auditory cortex [17], it was thought to be a par-
ticularly good candidate technology for the assessment of sensory gating.
Methods
Participants
The present study was approved by the University of New Mexico Health Sciences
Center, Human Research Protections Office. Participants were recruited from the gen-
eral community of the city of Albuquerque, New Mexico, from the University of New
Mexico (UNM) Hospital’s Alcohol and Substance Abuse Program (ASAP), and from
the UNM Center for Alcoholism, Substance Abuse and Addictions (CASAA). Groups
were comprised of healthy controls (Controls, N = 4), participants with active alcohol de-
pendence (AUD-current, N = 6), and participants with full remission from alcohol depend-
ence for least 1 year (AUD-remission, N = 6). Table 1 shows the demographic composition
of each group.
General inclusion criteria were (1) age 18–45 years old, (2) ability and willingness to par-
ticipate in all study components, (3) functional facility with English language, (4) no
evidence of fetal alcohol syndrome, (5) no drinking in the 48 h prior to study participation,
(6) negative urine sample for presence of illicit drugs, (7) no history of neurological disorder
or disease, (8) no history of head injury with loss of consciousness > 5 min, (9) no evidence
of psychosis, (10) no current psychoactive medication use, and (11) no diagnosis of mental
retardation or of learning disability. General exclusion criteria: 1) DSM-IV diagnosis of
cocaine, heroin, methamphetamine, inhalant, or marijuana dependence. Table 2 provides
descriptive statistics of the drug and alcohol measures for each group.
Diagnostic determination was made using the Structured Clinical Interview for DSM-
IV-IP (SCID-IV; [18]; see also [19]). Inclusion criteria for the AUD-current group (N =
6) were (1) diagnosis of alcohol dependence, (2) active alcohol use within the past
30 days (i.e. not in early or full remission), that included at least one episode of binge
drinking (5 or more drinks per occasion for males, 4 or more drinks per occasion for
females). Inclusion criteria for the AUD-remission group (N = 6) were (1) History of al-
cohol dependence (as determined by the SCID-IV) and (2) at least 1 year of complete
remission from alcohol and illicit drug use. The Control group (N = 4) was comprised
of healthy individuals who were either non-drinkers or mild social drinkers with no his-
tory of diagnosis with substance use disorder. General exclusion criteria were (1) diag-
nosis of schizophrenia spectrum or other psychotic disorder, and (2) a first-degree
Table 1 Group demographics
Controls AUD-Current AUD-Remission
Age (in years) 36.50 (10.91) 37.50 (7.87) 34 (4.69)
Gender 1 M/3 F 4 M/2 F 5 M/1 F
Education (in years) 14.25 (1.71) 13 (1.79) 13 (1.79)
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relative with schizophrenia. Table 3 provides information regarding co-morbid SCID-
IP-assessed lifetime diagnoses.
Procedures
MRI and MRS data acquisition
MRI and 1H-MRS data were collected on a Siemens 3-Tesla TrioTIM scanner using a
12-channel radiofrequency head coil. T1-weighted images were collected in the sagittal
plane using a five-echo 3D MPRAGE sequence (TR/TE/TI = 2530/1.64, 3.5, 5.36, 7.22,
9.08/1200 ms, flip angle = 7°, field of view = 256 × 256 mm, matrix = 256 × 256, 1 mm
thick slice, 192 slices, GRAPPA acceleration factor = 2). Using these images, a single
1H-MRS voxel was positioned in the bilateral medial frontal cortex directly superior to
the corpus callosum, containing anterior cingulate, middle frontal, and superior frontal gyri
(see Fig. 1; [3]. A PRESS (point-resolved spectroscopy) sequence (TR/TE = 1.5 s/40 ms,
voxel size = 20 × 30 × 20 mm, averages = 192) was collected, using an echo time (TE) of
40 ms for improved detection of Glu [12]. An unsuppressed water sequence for use as a
concentration reference and eddy current correction in post-processing was collected with
16 averages and otherwise identical parameters for each spectrum. Figure 1 depicts the
voxel location in a single MRI.
Table 2 Alcohol and other substance use variables by Group
Controls AUD-Current AUD-Remission
DrInC total score 1.75 (2.06) 40.67 (4.23) 0
Form-90 Drinks Per Drinking Day (DPDD) 1.34 (1.86) 19.19 (6.94) 0
Form-90 Percent Days Drinking (PDD) 3.28 % (5.65 %) 29.02 % (18.59 %) 0 % (0 %)
Form-90 lifetime weeks nicotine use 0 (0) 521.33 (546.84) 585.00 (459.77)
Form-90 number of days nicotine use 0 (0) 63.17 (48.99) 67.50 (37.65)
Form-90 number of cigarettes per day 0 (0) 11.33 (12.36) 5.00 (4.56)
Cannabis (lifetime use) 0 yes 4 yes 4 yes
Stimulants (lifetime use) 0 yes 2 yes 3 yes
Opioid (non-prescription; lifetime use) 0 yes 1 yes 1 yes
Cocaine (lifetime use) 0 yes 4 yes 4 yes
Hallucinogens (lifetime use) 0 yes 1 yes 2 yes
Table 3 Lifetime DSM-IV diagnoses by Group (number of subjects reporting history of diagnosis)
Controls AUD-Current AUD-Remission
Bipolar disorder 0 1 0
Depression 0 3 4
Dysthymia 0 2 1
Brief psychotic episode 0 0 1
Panic disorder 0 3 0
Agoraphobia 0 0 1
Social phobia 0 0 1
Obsessive compulsive symptoms 0 0 1
Posttraumatic stress disorder 0 2 1
Generalized anxiety disorder/anx dis NOS 0 6 1
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1H-MRS data analysis
Raw time-domain 1H-MRS data from 4.0 – 1.0 ppm in the spectral dimension were
analyzed using LCModel [20] with the unsuppressed water scan as a concentration
reference. Parameterized macromolecule intensities were included over the fitted spectral
region (the LCModel macromolecule intensity set MM20). As a quality-assurance measure,
LCModel produces a Cramer-Rao lower bound (CRLB) of the fit to the peak of interest. If
this value was greater than 20 %, the fit was deemed unreliable and excluded from analysis.
Metabolite concentrations in molality units of mmol/kg of tissue water were computed for
total creatine plus phosphocreatine (Cre), total choline-containing compounds (Cho), myo-
inositol (Ins), total N-acetylaspartate plus N-acetyl-aspartylglutamate (NAAG), glutamate
(Glu), and glutamine (Gln). To calculate brain tissue within the spectroscopic volume, T1-
weighted images were segmented into gray matter, white matter, and cerebrospinal fluid
(CSF) using SPM5. The spatial coordinates of the voxel and T1-weighted image were used
to register the voxel volume to the segmentation maps generated from the T1-weighted
image. Gray matter, white matter, and CSF percentage were then determined as the sum of
pixels within each tissue type divided by the total pixels in the voxel. Metabolite concentra-
tions were then computed, correcting for partial-volume CSF and T1 and T2 relaxation ef-
fects using methods described previously [21]. Fig. 2 shows a representative spectrum from
a control participant.
MEG auditory paired-click design
Presentation software was fully integrated with CTF data acquisition software to record
stimulus presentation in the MEG data file. Three millisecond binaural clicks were
presented in pairs, with a 500 millisecond inter-stimulus interval (ISI) between the first (S1)
and second (S2) click in the pair. Click pairs were delivered to participants with Etymotic
transducers placed outside the shielded room (to control electrical artifact) and conducted
through 2.5 meter plastic ear tubes. While there was no detectable jitter in stimulus delivery,
sound card and stimulus delivery hardware resulted in a 31 ms stimulus delay that was
corrected for during offline processing. Inter-trial interval (latency between click pairs) was
randomly varied between 7 and 12 s in 1-second steps. Prior to experimental procedures, a
hearing test was performed during which each subject’s hearing threshold was determined
using click stimuli presented through the Etymotic sound delivery system. Click stimuli
were then presented at 35 dB above this threshold. Click pairs were presented over a
roughly 35-minute data recording session.
MEG data collection
MEG data were recorded during presentation of the paired-click protocol. The data were
recorded on a VSM/CTF-Medtech Omega 275 whole-head biomagnetometer system
Fig. 1 1H-MRS voxel location in medial prefrontal cortex
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located at the Mind Research Network Imaging Center (Albuquerque, NM, USA). Vertical
and horizontal extra-ocular electrodes [electro-oculogram (EOG)] were placed to record
eye movements and two electrodes were placed to record heartbeat. Data were collected
with subjects comfortably seated in a soft chair with their head in a Dewar helmet
containing the MEG sensors. All data were collected at a digitization rate of 1200 Hz with
a 0.1–130 Hz bandpass filter and continuous data were stored for post-processing.
Noise reduction
MEG data were recorded within a three-layer (two μ-metal and one aluminum)
magnetically shielded room (Vacuumschmelze, GmbH & Co. KG, Hanau, Germany)
to reduce interference from ambient environmental magnetic fields to less than
0.15 T. To further reduce environmental magnetic noise, all MEG data were collected
applying CTF third-order synthetic gradient computations. To identify eye-blink and
muscle artifacts, two channels of electro-oculogram (EOG; vertical and horizontal) were
collected concurrently with MEG. Epochs were rejected if peak-to-peak signal strength for
the entire epoch exceeded 150 μV in any EOG channel or 3000 fT in any MEG channel.
One hundred twenty five click-pairs were presented to each participant and all partic-
ipants achieved at least 100 artifact-free trials for data averaging. Movement by partic-
ipants was monitored at all times by research assistants. Additionally, a head
localization function within CTF Data Acquisition Software was used to track pre-
and post-run head locations. Fiducial coil locations were recorded at the beginning of
each data collection run. When recording was complete, a post-run coil localization
was implemented allowing computation of how much the head moved (in cm) be-
tween the start and end of the recording. Head movement was deemed acceptable
if movement values were less than .5 cm in any plane.
MEG/MRI coregistration procedures
The purpose of co-registration procedures is to locate the position of the patient’s head on
the MRI relative to the MEG channels. This was accomplished by first positioning thee
Fig. 2 A typical 1H-MRS spectrum for a sample individual
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small localization coils at landmark locations (periauricular and nasion fiducial
points) on each participant prior to MEG data collection. From these data, the
patient’s head was located relative to the coordinate system fixed to the dewar (the
CTF dewar coordinate system). A new coordinate frame relative to the patient’s
head, known as the CTF MEG head coordinate system was then derived. During
coil placement procedures, data for 50 to 100 Polhemus digitizer points were col-
lected to record coil positions and define head shape. Following data collection,
CTF MRIConverter software was used to import Magnetic Resonance Imaging
(MRI) data and subsequently to produce an isotropic volumetric image file. Within
the CTF MRIViewer application, this image file was co-registered with the head
coordinate system produced by the CTF MEG System software. Coregistration was
then accomplished via a 2-stage process. Initially, the first author (RJT) used MRI-
Viewer interactive software to co-register MEG and MRI data. This co-registration
was then reviewed for accuracy by a second research team member.
MEG data reduction and source localization
VSM/CTF software was scripted to assure identical data preprocessing across participants.
First, to preserve data storage space, data were downsampled to 600 Hz. Second, 4–45 Hz
recursive Chebyshev II bandpass filters were applied to the continuous data. Using
the CTF interactive software program, MRViewer, a spherical volume conductor
approximating the inner skull surface was created. The resultant best-fit sphere
was saved in the head model file for dipole localization and in dipole files for
source computations. Using the CTF DipoleFit software package, two starting
points for the dipole fits were determined, one in each hemisphere. To place these
starting points, each individual’s unique spherical head model was first bisected in
the plane of the x-axis. Two radii were determined in this plane that connected
the center of the sphere to the furthest –y and + y points, and starting points were
placed at the midpoints of these radii. The CTF source localization software uses
an iterative non-linear minimization algorithm to compute the position and orien-
tation. Data from the full sensor array was used to compute two concurrent,
equivalent current dipoles (ECDs), localizing left- and right-hemisphere auditory
cortex on posterior, superior temporal gyrus (STG). Only ECDs with goodness-of-
fit values exceeding 75 % for S1 were accepted. Once localizations were deter-
mined, the M50 peak was defined as the first dorsal-oriented dipole occurring
prior to M100 and 40 to 80 ms poststimulus. For the S2 M50 response, it was as-
sumed that the location of the S2 dipole was the same as that of the S1 dipole,
and that the latency of the S2 dipole was within 10 ms of that associated with S1.
Peak S2 M50 source strength was computed based upon the highest peak within
10 ms of the S1 peak latency. M50 suppression for each hemisphere was expressed
as a ratio: S2 dipole peak strength divided by S1 dipole peak strength.
Statistical analysis
All statistical analyses were done using SPSS-version 20 software. Group differences in
1H-MRS metabolite concentrations were tested using univariate ANOVAs controlling
for the effect of age and gender. Group differences in ASG were tested using repeated
measures ANOVA, with left- and right-hemisphere ASG ratios included as the repeated
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measure, group as the between-subjects factor, and age and gender entered as covari-
ates. To assess the independent variance in sensory ASG ratios accounted for by Glu,
metabolite values were added to the repeated measures ANOVA as covariates. Since
gating ratios were computed on the basis of M50 S1 and S2 peak amplitudes, these
variables were considered as within-subjects dependent variables in a repeated
measures MANOVA (S1S2 amplitude and Hemisphere were entered as repeated




Descriptive statistics for 1H-MRS metabolite concentrations are presented in Table 4.
Mean Glu level was significantly lower in AUD-current relative to the Control and
AUD-remission groups (F(2,9) = 11.83, p = .04; partial eta squared = .890). Cramer-Rao
lower bounds (CRLB)were computed for all metabolites, and setting a maximum CRLB
value of 20 resulted in the rejection of four participant’s Gln values, resulting in a total
N = 12 for analysis of Gln.
MEG results
ASG ratios, and M50 amplitude and latencies for S1 and S2 are presented in Table 5. A
significant main effect for group was revealed, such that AUD-current had higher gating
ratios than the Control and AUD-remission groups (F(2,12) = 6.96, p = .01; partial eta
squared = .542).
Comparison of MEG and 1H-MRS
In analyses using ASG as dependent variables, a significant main effect for Glu was ob-
served (F(2,11) = 11.28, p = .006; partial eta squared = .506), such that higher Glu me-
tabolite concentration predicted lower sensory gating ratio bilaterally. Figure 3 shows
scatterplots for the relation between Glu and gating ratios. Other neurometabolite
values were considered individually as covariates (not corrected for multiple com-
parisons), and no effects were found for NAA (p = .75; partial eta squared = .063),
Cr (p = .74; partial eta squared = .065), Gln (p = .97; partial eta squared = .006), Cho
(p = .49; partial eta squared = .044) or Ins (p = .43; partial eta squared = .171).
Table 4 Neurometabolite levels by Group
Control AUD-current AUD-remission p-value a Partial eta squared
Glu 13.77 (1.17) 12.53 (1.27) 12.99 (1.74) .04 .89
Gln b 3.59 (0.49) 6.83 (2.36) 5.88 (2.72) .62 .68
Glx 17.03 (1.87) 18.78 (3.56) 18.34 (3.10) .14 .80
NAA 15.84 (0.36) 15.80 (1.25) 15.39 (0.72) .36 .61
Cre 13.42 (0.83) 13.61 (1.29) 14.16 (0.87) .87 .13
Ins 11.82 (1.61) 13.25 (2.02) 13.39 (0.65) .27 .71
Cho 2.89 (0.17) 3.01 (0.32) 3.29 (0.36) .90 .09
aOverall p-value for the effect of group, controlling for age and gender
bBased upon N = 12 (1.7)
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In analyses using S1S2 amplitude as dependent variables (S1S2 amplitude and
Hemisphere were entered as repeated measures), a significant main effect was found
for Group (F(2,11) = 7.17, p = .03; partial eta squared = .443), such that the current-AUD
group had higher ECD amplitudes overall. No main effect was found for Glu (p = .89;
partial eta squared = .002), but a significant two-way Glu*S1S2 amplitude interaction
emerged (F(1,9) = 5.80, p = .04; partial eta squared = .345). To test the independent
effect of Glu on S1 and S2 amplitude, a regression analysis was used, with Glu as the
dependent variable and mean S1 and S2 (averaged across hemisphere) and age as pre-
dictors. Age (beta = .63, p = .01) and S1 amplitude (beta = .65, p = .03) were positively
correlated with Glu level, and S2 amplitude was negatively correlated with Glu level
(beta = -.95, p = .005).
In analyses using S1S2 latency as dependent variables, similar repeated measures
MANOVA were used (S1S2 latency and Hemisphere were entered as repeated mea-
sures), with Group as the between-subjects factor, and Gender and Age considered as
covariates. A main effect of Group was found (F(1,9) = 4.35, p = .05; partial eta
squared = .491), such that the AUD-current group had a shorter mean latency relative
to the Control and AUD-remission groups. No effect was found for Glu (p = .59; partial
eta squared = .045) when it was added as a covariate.



















13.95 (4.45) 64.83 (15.36) 22.76 (6.13) 54.45 (9.51) 15.34 (5.13) 66.66 (6.96)
Left hemisphere
S2
6.34 (1.99) 62.25 (15.52) 15.83 (5.32) 52.86 (6.92) 7.98 (2.90) 65.34 (3.62)
Left hemisphere
(S2/S1)
.47 (.09) NA .69 (.18) NA 0.52 (.10) NA
Right hemisphere
S1
12.42 (3.36) 62.78 (10.79) 10.72 (.87) 50.57 (8.06) 11.90 (2.45) 63.00 (8.98)
Right hemisphere
S2
6.25 (2.02) 62.75 (13.22) 6.77 (1.01) 55.27(7.76) 4.95 (1.75) 60.68 (9.22)
Right hemisphere
S2/S1
.44 (.02) NA .58 (.13) NA .40 (.14) NA
Fig. 3 Scatterplots showing distributions of 1H-MRS Glu with left-hemisphere (Beta = −.73, p = .001) and
right- hemisphere (Beta = −.67, p = .004) sensory gating ratios
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Discussion
The primary hypothesis that impairment in ASG would be found in the AUD-current
and AUD-remission groups was only partly supported. ASG ratios were found to be
equivalent in the Control and AUD-Remission groups, and significantly elevated only in
the AUD-current group. A test of the second hypothesis, that Glu level would independ-
ently predict ASG ratios was supported, in that greater Glu concentration strongly pre-
dicted ASG ratios whether the effects of group, age and gender were controlled for or
not. To better understand the nature of this effect, gating, latency and amplitude of the
subcomponent measure comprising the ASG ratios were analyzed with respect to Glu.
Averaging across hemispheres, Glu was positively correlated with S1 amplitude, nega-
tively correlated with S2 amplitude, and unrelated to latency.
Although not entirely consistent with the initial hypotheses, the pattern of results
indicates important relationships between AERPs, auditory processing, and Glu levels.
Consistent with Glu’s role as the brain’s primary excitatory neurotransmitter, elevated
Glu levels predicted greater S1 amplitude. The finding that increased Glu levels are
related to reduced S2 amplitude are consistent with findings of induced impairment in
mismatch negativity (MMN) and P3 oddball (P3) paradigms with ketamine challenge.
Ketamine is a Glu antagonist, and ketamine induced changes in AERP-related modulation
assessed using MMN and P3 involve the reduction of the typical MMN and P3 effect size
[22]. Consistent with these findings, improvement in auditory processing, assessed in
terms of reduced ASG ratio, was predicted by higher Glu levels across groups. The results
of this study are also consistent with the findings of Chang et al. [23], showing that higher
Glu level was associated with smaller S2 amplitude in ASG gating.
The present findings are also generally consistent with the prevailing literature
regarding disruption of Glu system functioning in AUD [3]. That Glu concentrations
assessed in ACC were associated with the sensory gating system, which is purportedly
mediated by medial temporal cortex functioning [6], was not surprising, as Glu is ubiqui-
tous in the cerebral hemispheres and is the major excitatory neurotransmitter in the brain.
It is only possible to speculate about the mechanism underlying the relationship between
Glu and sensory gating based upon present data, though the current hypotheses were con-
ceived on the basis of our knowledge of Glu changes in alcohol dependence. Alcohol binds
to the N-methyl-D-aspartate Glu receptor (NMDAR), ultimately enhancing NMDAR gene
expression and changing patterns of membrane depolarization [24]. Chronic alcohol inges-
tion inhibits the NMDAR functioning and can result in neuronal hyperexcitability and exci-
totoxicity upon withdrawl [25-29].
Conclusions
The results of this study are complicated by many factors, perhaps the most serious of
which is the small sample size. To address that issue, effect size statistics were included in
the reported results. The group effect on neuromtabolites Gln, Glx, NAA, and Ins were of
moderate effect size, emphasizing the importance of replication in a larger sample. Simi-
larly, there is evidence of a lateralization effect with regard to S1 signal strength in the
MEG data for the AUD-current group, further investigation of which necessarily warrants
a larger study. Measurement of neurometabolite levels in event-related dipole locations
might have added greater face validity to the present Glu findings. In addition, accurate
measurement of GABA, which requires special acquisition procedures owing to
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overlapping resonances with Cre, Glu and Gln, would help elucidate the overall gluta-
matergic turnover in these subjects. and perhaps shed light on the role of Gln, which in
this study was found to be elevated in both AUD-current and AUD-remission, and which
is consistent with previously published results [3].
Both Glu metabolite levels [30] and auditory sensory gating ratio [6] are known to be
abnormal in schizophrenia. As the effect of comorbidity of alcohol use disorders and
schizophrenia on ASG is additive [3], one potentially important next step is to investigate
how Glu and other neurometabolite metabolite levels are affected by the use of alcohol in
schizophrenia. In the present study, sensory gating was defined only in terms of the 50 ms
component of the event related field, partly to constrain the number of hypotheses tested
in this small, but clinically interesting sample. It is known, however, that gating ratios
based upon other components of the auditory evoked potential in a paired-click paradigm
(e.g., N100, P200) contain additional and independent information [31], and a next step in
this research might be to test for relationships between neurometabolite levels and ASG
computed in terms of possible neurophysiologic components.
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